Insulin detemir:A once-daily long-acting basal insulin analogue with clear weight and hypoglycaemia advantages

Abstract

Insulin detemir is a new class of long-acting basal insulin analogue manufactured by Novo Nordisk A/S. The unique mechanism of protracted action designed for insulin detemir provides a stable and prolonged action of glycemic control up to 24 hours, reduced variability in glucose level, and a good predictable glucose profile. Many clinical trials demonstrated that subjects treated with insulin detemir achieved good glycemic control with a lower risk of experiencing hypoglycemic episodes and less weight gain compared with subjects treated by other basal insulin. The good safety and tolerability of insulin detemir is confirmed in postauthorization observational studies. This article reviews the pharmacologic characteristics of insulin detemir and the updates of its application in the clinical trials and routine practice. Key words: Diabetes mellitus; Insulin analogue; Insulin detemir